These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. Tran H; Anand SS JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585 [TBL] [Abstract][Full Text] [Related]
3. Ticlopidine: a new platelet aggregation inhibitor. Ito MK; Smith AR; Lee ML Clin Pharm; 1992 Jul; 11(7):603-17. PubMed ID: 1617911 [TBL] [Abstract][Full Text] [Related]
4. Ticlopidine: a new antiplatelet agent for cerebrovascular disease. Robert S; Miller AJ; Fagan SC Pharmacotherapy; 1991; 11(4):317-22; discussion 322-5. PubMed ID: 1923914 [TBL] [Abstract][Full Text] [Related]
5. Ticlopidine: a new antiplatelet agent for the secondary prevention of stroke. Murray JC; Kelly MA; Gorelick PB Clin Neuropharmacol; 1994 Feb; 17(1):23-31. PubMed ID: 8149356 [TBL] [Abstract][Full Text] [Related]
6. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Haynes RB; Sandler RS; Larson EB; Pater JL; Yatsu FM Arch Intern Med; 1992 Jul; 152(7):1376-80. PubMed ID: 1627017 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet agents for secondary prevention of ischemic stroke. Majid A; Delanty N; Kantor J Ann Pharmacother; 2001 Oct; 35(10):1241-7. PubMed ID: 11675854 [TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy in the prevention of ischaemic stroke. Verry M; Panak E; Cazenave JP Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242 [TBL] [Abstract][Full Text] [Related]
9. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Jamieson DG; Parekh A; Ezekowitz MD J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203 [TBL] [Abstract][Full Text] [Related]
10. Antiplatelet therapy in the treatment of cerebrovascular disease. Couch JR Clin Cardiol; 1993 Oct; 16(10):703-10. PubMed ID: 8222382 [TBL] [Abstract][Full Text] [Related]
11. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Lenz TL; Hilleman DE Ann Pharmacother; 2000 Nov; 34(11):1283-90. PubMed ID: 11098344 [TBL] [Abstract][Full Text] [Related]
12. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Reaume KT; Regal RE; Dorsch MP Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394 [TBL] [Abstract][Full Text] [Related]
13. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease. Gebel JM Am J Cardiovasc Drugs; 2010; 10(2):115-24. PubMed ID: 20334449 [TBL] [Abstract][Full Text] [Related]
15. Role of ticlopidine for prevention of stroke. Albers GW Stroke; 1992 Jun; 23(6):912-6. PubMed ID: 1595115 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Bellavance A Stroke; 1993 Oct; 24(10):1452-7. PubMed ID: 8378945 [TBL] [Abstract][Full Text] [Related]
17. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Hermosillo AJ; Spinler SA Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734 [TBL] [Abstract][Full Text] [Related]
18. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. McTavish D; Faulds D; Goa KL Drugs; 1990 Aug; 40(2):238-59. PubMed ID: 2226215 [TBL] [Abstract][Full Text] [Related]
19. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. Kirshner HS Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660 [TBL] [Abstract][Full Text] [Related]